- Home
- SOPH vs VNDA Comparison
SOPH vs VNDA Comparison
Compare SOPH & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOPH
- VNDA
- Stock Information
- Founded
- SOPH 2011
- VNDA 2002
- Country
- SOPH Switzerland
- VNDA United States
- Employees
- SOPH N/A
- VNDA N/A
- Industry
- SOPH Biotechnology: Biological Products (No Diagnostic Substances)
- VNDA Biotechnology: Pharmaceutical Preparations
- Sector
- SOPH Health Care
- VNDA Health Care
- Exchange
- SOPH Nasdaq
- VNDA Nasdaq
- Market Cap
- SOPH 247.0M
- VNDA 270.2M
- IPO Year
- SOPH 2021
- VNDA 2006
- Fundamental
- Price
- SOPH $3.13
- VNDA $4.94
- Analyst Decision
- SOPH Strong Buy
- VNDA Strong Buy
- Analyst Count
- SOPH 3
- VNDA 2
- Target Price
- SOPH $7.00
- VNDA $15.50
- AVG Volume (30 Days)
- SOPH 30.7K
- VNDA 643.5K
- Earning Date
- SOPH 11-05-2024
- VNDA 11-06-2024
- Dividend Yield
- SOPH N/A
- VNDA N/A
- EPS Growth
- SOPH N/A
- VNDA N/A
- EPS
- SOPH N/A
- VNDA N/A
- Revenue
- SOPH $64,488,000.00
- VNDA $190,858,000.00
- Revenue This Year
- SOPH $7.34
- VNDA $5.13
- Revenue Next Year
- SOPH $20.25
- VNDA $42.65
- P/E Ratio
- SOPH N/A
- VNDA N/A
- Revenue Growth
- SOPH 9.85
- VNDA N/A
- 52 Week Low
- SOPH $2.70
- VNDA $3.46
- 52 Week High
- SOPH $7.37
- VNDA $6.75
- Technical
- Relative Strength Index (RSI)
- SOPH 39.02
- VNDA 50.36
- Support Level
- SOPH $3.40
- VNDA $4.82
- Resistance Level
- SOPH $3.99
- VNDA $5.55
- Average True Range (ATR)
- SOPH 0.26
- VNDA 0.22
- MACD
- SOPH -0.05
- VNDA -0.02
- Stochastic Oscillator
- SOPH 0.00
- VNDA 32.22
About SOPH SOPHiA GENETICS SA
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS), Fanapt for the treatment of schizophrenia and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from HETLIOZ product sales.